Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial results

Blood (2024) 144 (22): 2295–2307.

https://doi.org/10.1182/blood.2024024789

Published: 2024

Includes: Supplemental data

Journal Articles

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy

Blood blood.2024025366.

https://doi.org/10.1182/blood.2024025366

Published: 2024

Includes: Supplemental data

Journal Articles

Bispecific CD33/CD123 Targeted Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia

Justin C. Boucher, Bishwas Shrestha, Paresh Vishwasrao, Mark B. Leick, Nhan Tu, Tayyebb Ghafoor, Kayla M. Reid, Kristen Spitler, Bin Yu, Marcela V. Maus, Marco L. Davila

Blood (2022) 140 (Supplement 1): 10275–10276.

https://doi.org/10.1182/blood-2022-163299

Published: 2022

Journal Articles

Baseline Systemic Inflammatory Markers Interleukin 6 and Ferritin Are Associated with Toxicities and Progression-Free Survival in Multiple Myeloma Patients Treated with Idecabtagene Vicleucel

Blood (2022) 140 (Supplement 1): 12778–12780.

https://doi.org/10.1182/blood-2022-158080

Published: 2022

Journal Articles

Phase I Trial of CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) to Achieve Remissions in Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)

Blood (2022) 140 (Supplement 1): 886–888.

https://doi.org/10.1182/blood-2022-168175

Published: 2022

Journal Articles

Biphasic Neutrophil Recovery after CD19 CART in R/R LBCL Is Associated with Superior PFS/OS, Robust CAR T-Cell Expansion in Relation to Baseline Tumor Volume, and a Decrease of Systemic Inflammation over Time

Blood (2022) 140 (Supplement 1): 4549–4551.

https://doi.org/10.1182/blood-2022-167632

Published: 2022

Journal Articles

Phase 1/1b Safety Study of Prgn-3006 Ultracar-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

Blood (2022) 140 (Supplement 1): 10313–10315.

https://doi.org/10.1182/blood-2022-169142

Published: 2022

Journal Articles

A Novel IL2Rα-/- Model for CAR-T Toxicity in Acute Lymphoblastic Leukemia Recapitulates Cytokine Release Syndrome and Neutropenia

Payal Goala, Hiroshi Kotani, Zhang Yongliang, Kayla M. Reid, Justin C. Boucher, Constanza Savid-Frontera, Sae Bom Lee, Nolan Beatty, Michael D. Jain, Marco L. Davila

Blood (2022) 140 (Supplement 1): 1176–1177.

https://doi.org/10.1182/blood-2022-165562

Published: 2022

Journal Articles

Baseline CRP and Ferritin Identify Patients at High Risk of Poor Outcomes after Axicabtagene Ciloleucel Despite Corticosteroid Prophylaxis

Blood (2022) 140 (Supplement 1): 4678–4680.

https://doi.org/10.1182/blood-2022-171084

Published: 2022

Journal Articles

Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma

Michael D. Jain, Bachisio Ziccheddu, Caroline A. Coughlin, Rawan Faramand, Anthony J. Griswold, Kayla M. Reid, Meghan Menges, Yonghong Zhang, Ling Cen, Xuefeng Wang, Mohammad Hussaini, Ola Landgren, Marco L. Davila, Jonathan H. Schatz, Frederick L. Locke, Francesco Maura

Blood (2022) 140 (5): 491–503.

https://doi.org/10.1182/blood.2021015008

Published: 2022

Includes: Supplemental data

Journal Articles

CAR T-cell hematotoxicity: is inflammation the key?

Rawan G. Faramand, Marco L. Davila

Blood (2021) 138 (24): 2447–2448.

https://doi.org/10.1182/blood.2021012876

Published: 2021

Journal Articles

Genomic Drivers of Large B-Cell Lymphoma Resistance to CD19 CAR-T Therapy

Michael D. Jain, Bachisio Ziccheddu, Caroline A. Coughlin, Rawan Faramand, Anthony J. Griswold, Kayla M Reid, Ola Landgren, Frederick L. Locke, Francesco Maura, Marco L. Davila, Jonathan H. Schatz

Blood (2021) 138 (Supplement 1): 42.

https://doi.org/10.1182/blood-2021-148605

Published: 2021

Journal Articles

Concurrent Monitoring of Peripheral Blood Circulating Tumor DNA and Circulating Tumor Cells in Relapsed/Refractory Follicular Lymphoma Patients Post Axicabtagene Ciloleucel, a Single Center Experience

Sameh Gaballa, Julio C. Chavez, Michael D. Jain, Meghan A Menges, Kayla M Reid, David Kaldas, Bijal D. Shah, Marco L. Davila, Frederick L. Locke

Blood (2021) 138 (Supplement 1): 2397.

https://doi.org/10.1182/blood-2021-149559

Published: 2021

Journal Articles

Primary Progression on Frontline Therapy for Diffuse Large B-Cell Lymphoma Is Associated with a Poor Outcome Despite Subsequent CD19 Targeted CAR T-Cell Therapy

Ariel Perez Perez, Grace Johnson, Kedar Patel, Brian Arciola, Anthony Wood, Christina A Bachmeier, Julio C. Chavez, Bijal D. Shah, Farhad Khimani, Taiga Nishihori, Aleksandr Lazaryan, Marco L. Davila, Rahul Mhaskar, Frederick L. Locke, Sameh Gaballa, Michael D. Jain

Blood (2021) 138 (Supplement 1): 3855.

https://doi.org/10.1182/blood-2021-150735

Published: 2021

Journal Articles

Phase 1/1b Safety Study of Prgn-3006 Ultracar-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

David A. Sallman, Hany Elmariah, Kendra Sweet, Chetasi Talati, Asmita Mishra, Cheryl A Cox, Roshanak Semnani, Rutul R Shah, Helen Sabzevari, Marion Chakiath, Justin Uthuppan, Amy Lankford, Chen Wang, Eric Padron, Andrew T. Kuykendall, Rami S. Komrokji, Jeffrey E. Lancet, Marco L. Davila, Nelli Bejanyan

Blood (2021) 138 (Supplement 1): 825.

https://doi.org/10.1182/blood-2021-152692

Published: 2021

Journal Articles

Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy

Kitsada Wudhikarn, Jessica R. Flynn, Isabelle Rivière, Mithat Gönen, Xiuyan Wang, Brigitte Senechal, Kevin J. Curran, Mikhail Roshal, Peter G. Maslak, Mark B. Geyer, Elizabeth F. Halton, Claudia Diamonte, Marco L. Davila, Michel Sadelain, Renier J. Brentjens, Jae H. Park

Blood (2021) 138 (7): 531–543.

https://doi.org/10.1182/blood.2020009515

Published: 2021

Includes: Supplemental data

Journal Articles

Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma

Blood (2021) 137 (19): 2621–2633.

https://doi.org/10.1182/blood.2020007445

Published: 2021

Includes: Supplemental data

Journal Articles

Results from the Phase I Clinical Studies Evaluating Cyad-01, a First-Generation NKG2D CAR T-Cell Product in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-139609

Published: 2020

Journal Articles

A Phase 1/1b Safety Study of Prgn-3006 Ultracar-T™ in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndrome

David A. Sallman, MD, Hany Elmariah, MD MS, Kendra L. Sweet, MD MS, Chetasi Talati, MD, Asmita Mishra, MD, Linda L. Kelley, PhD, Amy Lankford, PhD, Tim Chan, PhD, Rutul R Shah, Eric Padron, MD, Rami S. Komrokji, MD, Jeffrey E. Lancet, MD, Helen Sabzevari, PhD, Marco L. Davila, MD PhD, Nelli Bejanyan, MD

Blood (2020) 136 (Supplement 1): 17.

https://doi.org/10.1182/blood-2020-139417

Published: 2020

Journal Articles

Biological and Clinical Impact of JAK2/mTOR Blockade in Gvhd Prevention: Preclinical and Phase I Trial Results

Joseph Pidala, MD, Kelly Walton, Hany Elmariah, MDMS, Jongphil Kim, PhD, Asmita Mishra, MD, Nelli Bejanyan, MD, Taiga Nishihori, MD, Farhad Khimani, MBBS, Lia Perez, MD, Rawan Faramand, MD, Marco L. Davila, MD PhD, Michael Nieder, MD, Nicholas Lawrence, PhD, Harshani Lawrence, PhD, Claudio Anasetti, MD, Said Sebti, PhD, Brian C. Betts, MD

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-133874

Published: 2020

NARROW

JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial results

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy

Bispecific CD33/CD123 Targeted Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia

Baseline Systemic Inflammatory Markers Interleukin 6 and Ferritin Are Associated with Toxicities and Progression-Free Survival in Multiple Myeloma Patients Treated with Idecabtagene Vicleucel

Phase I Trial of CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) to Achieve Remissions in Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)

Biphasic Neutrophil Recovery after CD19 CART in R/R LBCL Is Associated with Superior PFS/OS, Robust CAR T-Cell Expansion in Relation to Baseline Tumor Volume, and a Decrease of Systemic Inflammation over Time

Phase 1/1b Safety Study of Prgn-3006 Ultracar-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

A Novel IL2Rα-/- Model for CAR-T Toxicity in Acute Lymphoblastic Leukemia Recapitulates Cytokine Release Syndrome and Neutropenia

Baseline CRP and Ferritin Identify Patients at High Risk of Poor Outcomes after Axicabtagene Ciloleucel Despite Corticosteroid Prophylaxis

Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma

CAR T-cell hematotoxicity: is inflammation the key?

Genomic Drivers of Large B-Cell Lymphoma Resistance to CD19 CAR-T Therapy

Concurrent Monitoring of Peripheral Blood Circulating Tumor DNA and Circulating Tumor Cells in Relapsed/Refractory Follicular Lymphoma Patients Post Axicabtagene Ciloleucel, a Single Center Experience

Primary Progression on Frontline Therapy for Diffuse Large B-Cell Lymphoma Is Associated with a Poor Outcome Despite Subsequent CD19 Targeted CAR T-Cell Therapy

Phase 1/1b Safety Study of Prgn-3006 Ultracar-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy

Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma

Results from the Phase I Clinical Studies Evaluating Cyad-01, a First-Generation NKG2D CAR T-Cell Product in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

A Phase 1/1b Safety Study of Prgn-3006 Ultracar-T™ in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndrome

Biological and Clinical Impact of JAK2/mTOR Blockade in Gvhd Prevention: Preclinical and Phase I Trial Results

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only